Security record · archived quarter
PPH
VanEck Pharmaceutical ETF · Financial Services · Asset Management
5Tracked holders
—Δ holders
69.03KShares held
$6.31MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 42 | 0 | 4.70M | $514.35M | +3 | −3 |
| Q1 2026 | 43 | 0 | 4.47M | $464.64M | +6 | −6 |
| Q4 2025 | 43 | -2 | 5.30M | $546.75M | +1 | −3 |
| Q3 2025 | 10 | +2 | 3.22M | $291.27M | +2 | — |
| Q2 2025 | 5 | +1 | 92.39K | $8.13M | +2 | −1 |
| Q1 2025 | 3 | -2 | 1.37M | $124.90M | +1 | −3 |
| Q4 2024 | 5 | 0 | 197.06K | $17.00M | +1 | −1 |
| Q3 2024 | 5 | 0 | 123.94K | $11.78M | +1 | −1 |
| Q2 2024 | 5 | — | 69.03K | $6.31M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 25.90K | — | $2.37M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Two Sigma Investments ✦ | 16.20K | — | $1.48M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | D. E. Shaw & Co. ✦ | 14.29K | — | $1.31M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 7.27K | — | $665,151 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 5.37K | — | $491,431 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 147 holders, 7.59M shares, $716.28M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API